Quick Facts

• Therapeutic Domain: Conditions linked to excessive prolactin levels in the body.
• Primary Use: Addressing hyperprolactinemic disorders.
• Associated Conditions: Managing symptoms related to pituitary adenomas.

---

Cabergolin-CT is a therapeutic agent used for managing hyperprolactinemic disorders in adult patients. These conditions are characterized by higher than normal levels of the hormone prolactin, which can affect various body functions.

Its primary use is in the treatment of prolactin-related disorders, whether the cause is unknown (idiopathic) or due to pituitary adenomas that secrete the prolactin hormone. The compound is associated with managing symptoms that may include issues with the menstrual cycle, infertility, and related hormonal imbalances.

Treatment aims to help normalize prolactin concentrations in the blood. Regular consultation with a healthcare professional is necessary to monitor the patient's condition and determine the continued need for therapy.

Who Can and Cannot Use Cabergolin-CT?

Cabergolin-CT (Cabergoline) eligibility is strictly defined by regulatory authorities and centers on absolute non-eligibility (contraindications) and conditional restrictions. The medicine is primarily approved for use in adult patients with hyperprolactinemic disorders.

Absolute Non-Eligibility

Cabergolin-CT is contraindicated and must not be used if a patient has a known hypersensitivity to cabergoline or any other ergot derivatives. Use is also strictly prohibited in patients with uncontrolled hypertension or a history of specific cardiac valvular disorders or fibrotic conditions (pleural, pulmonary, or retroperitoneal) as defined by official labeling.

Conditional Use and Age Restrictions

Safety and efficacy have not been established in pediatric patients under 16 years of age. Caution is required when prescribing to geriatric patients (aged 65 and older) and those with severe hepatic insufficiency.

Regarding reproductive status, use during pregnancy is permitted only if clearly needed. Furthermore, women treated for hyperprolactinemia are advised not to breast-feed, as the drug is expected to inhibit lactation. The use of Cabergolin-CT is specifically avoided for the purpose of suppressing normal postpartum milk production.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Cabergoline (Cabergolin-CT) as described in authoritative regulatory documents.

Documented Interaction Restrictions

Co-administration is not recommended with medicinal products classified as Dopamine D2 receptor antagonists, due to the risk of pharmacodynamic antagonism. This restriction specifically applies to agents like phenothiazines, butyrophenones, thioxanthenes, and metoclopramide. Additionally, long-term treatment is not advised in combination with other ergot alkaloids, as regulatory data regarding possible interactions are insufficient.

Category of Interacting Agents	Official Interaction Outcome
Antihypertensive Agents	Potential for additive hypotensive effect (including orthostatic hypotension), requiring caution.
Macrolide Antibiotics	Co-use should be avoided as it may result in elevated cabergoline plasma levels, based on findings with similar ergot derivatives.
Food	Food does not alter the kinetics of Cabergoline, and administration can occur with or without a meal.

Population and Metabolic Notes

The interaction profile includes a note regarding patients with severe hepatic insufficiency (Child-Pugh Class C), where a greater increase in systemic drug exposure (AUC) is a documented outcome. The drug is described as undergoing minimal Cytochrome P-450 mediated metabolism, and studies indicate no significant pharmacokinetic interaction with medicines such as L-dopa or Selegiline.

Targeted Activation of Pituitary mathbfDmathbf2 Receptors

Cabergoline acts as an agonist with high receptor affinity that selectively targets and activates the Dopamine Dmathbf2 receptors, primarily located on the hormone-producing lactotroph cells in the anterior pituitary gland. This interaction mimics the body's natural inhibitory signal, utilizing the tuberoinfundibular pathway to modulate activity within the neuroendocrine system.

---

Suppression via Intracellular Signaling Cascade

The activation of the Dmathbf2 receptor initiates a precise Gmathbfi-protein coupled cellular signaling cascade. This mechanism effectively inhibits adenylyl cyclase, leading to a reduction in the internal messengers ( cAMP and Ca^2+) required for hormone production and release. This direct suppression of the cell's secretory function results in the sustained inhibition of prolactin secretion as the key physiological change.

---

Specificity and Pharmacodynamic Constraints

While highly selective for Dmathbf2 receptors, the molecule also exhibits lower-affinity agonism at off-target receptors, notably the mathbf5-HTmathbf2B receptor, which is an inherent component of its mechanistic activity. Furthermore, the mechanism’s functional capacity can be subject to pharmacodynamic constraints, such as receptor resistance, which places inherent limits on the biological response in certain contexts.

Cabergolin-CT is an oral medication with a precise twice-weekly administration schedule, a method designed to align the drug's long duration of action with the goal of maintaining hormonal balance. The sole route of administration is oral via tablets, which are structurally scored to facilitate the accurate division necessary for low-dose starting regimens and precise titration.

Dosing and Schedule Principles

The regimen is initiated with a starting dose of 0.25 mg taken twice weekly. While the tablets may be administered with or without food, it is suggested that the medication be taken with meals to potentially improve gastrointestinal tolerability. Subsequent dose adjustments follow a specific protocol; the dosage may be increased by 0.25 mg twice weekly increments at intervals of no less than four weeks after assessing serum prolactin levels. The common therapeutic range is typically up to 2 mg per week. For specific populations, such as pediatric patients under 16, safety and efficacy have not been established.

Procedural Use and Course Duration

The overall protocol requires a specific procedural step: a clinical evaluation, including an echocardiogram, must be performed before the initiation of therapy.

The duration of the regimen is tied directly to hormonal response. Discontinuation of the twice-weekly schedule may be considered only after normal serum prolactin levels have been maintained for a period of six months, followed by subsequent periodic monitoring to guide any potential need to reinstitute therapy.

Research Evidence / Overview of Studies for Cabergolin-CT

Evidence for Use in Hyperprolactinemic Disorders

Research on Cabergolin-CT has included numerous Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in research contexts involving adult patients with hyperprolactinemia, a condition characterized by high prolactin levels. Researchers primarily examined outcomes related to systemic or functional imbalance, such as shifts in the serum prolactin (PRL) biomarker toward a normal range, and changes in associated clinical signs like menstrual irregularity or unwanted milk production.

Studies monitored how these symptoms evolved in the observed populations. Research highlights changes measured during the study period, including instances where PRL biomarker changes were monitored in studies. Some trials, including those comparing the treatment to older medicines in the same class, described patterns observed in the studies. Research explored the relationship between the drug's use and the observed changes in the prolactin levels.

While a significant amount of evidence exists, the quality of that evidence varies across studies. Variability (heterogeneity) in how specific outcomes, such as defining "normal prolactin levels" or "symptom resolution," were measured can influence the overall picture.

---

Evidence for Use in Prolactin-Secreting Pituitary Adenomas

The research base includes comparative cohort studies and long-term observational reviews that have explored the use of the drug in patients with tumors that secrete prolactin, known as prolactinomas. These studies monitored adult patients diagnosed with both small (micro-) and large (macro-) prolactinomas. Research examined two main outcomes: the change in the PRL biomarker and the adjustment in tumor size, which was measured radiologically using imaging over defined time intervals.

Studies report how tumor volume evolved in the observed populations, with findings describing patterns where changes in tumor volume were monitored for many participants. Research also describes patterns of PRL and tumor volume monitoring when the drug was continued for several years. These findings contribute to the broader evidence landscape by showing patterns related to tumor volume and the prolactin biomarker.

---

Research on Drug Withdrawal and Recurrence

Studies exploring what happens when patients stop using Cabergolin-CT are primarily composed of systematic reviews and meta-analyses of observational cohort studies. The research examined the time-to-recurrence (how long it took for prolactin levels to rise again) and the proportion of patients who maintained normal prolactin levels after cessation. These studies focused on patients who had achieved sustained normalization of prolactin levels prior to withdrawal.

Studies report on the patterns of prolactin levels for a proportion of individuals after stopping the medication, although the findings were mixed. Studies report how symptoms evolved in the observed populations, and the data show patterns related to the risk of prolactin levels increasing again. The evidence suggests that ongoing monitoring after cessation may be relevant.

A key limitation is the high statistical variability (heterogeneity) across studies regarding the precise proportion of patients who maintain remission long-term. This makes it challenging to establish a consistent rate of continued remission. Furthermore, the optimal duration of initial therapy before withdrawal remains an area of ongoing study.

Common questions about Cabergolin-CT (FAQ)

Q: Is Cabergolin-CT typically prescribed for short-term or long-term conditions?

Official documents indicate that treatment duration is guided by hormonal response and may be long-term, lasting until a sustained period of normal prolactin levels is achieved. Regulatory warnings note that serious safety considerations are primarily associated with continuous, long-term exposure to the medicine. Discontinuation is generally followed by a period of ongoing monitoring.

Q: Is it common to experience changes in mood or behavior while taking Cabergolin-CT?

Official product information lists Depression as a common effect of Cabergolin-CT. Furthermore, less common but documented serious reactions include Impulse Control Disorders, such as pathological gambling and hypersexuality.

Q: Can Cabergolin-CT cause feelings of dizziness or lightheadedness, and how is this managed?

Dizziness is a very common effect, while Postural Hypotension (lightheadedness when standing up) is also commonly reported. Regulatory guidance mentions that taking the medicine with meals may potentially improve gastrointestinal tolerability.

Q: What are the guidelines regarding driving or operating machinery while undergoing treatment with Cabergolin-CT?

Official warnings advise caution regarding activities that require full attention, such as driving or operating machinery. This caution is based on the potential for side effects including somnolence (drowsiness) and hypotension (low blood pressure).

Q: How soon can a patient typically expect to see results or changes after starting Cabergolin-CT?

Official prescribing information indicates that the dose is adjusted after monitoring the response, which includes assessing serum prolactin levels at intervals of no less than four weeks. This timeframe is used to measure the initial biological changes.

Q: Is Cabergolin-CT considered a cure for the underlying condition, or is it a management tool?

The drug is used to help the body achieve and maintain normal hormonal balance by suppressing prolactin secretion. Official documents noting that therapy may need to be reinstituted after cessation suggest the drug functions primarily as a management tool.

Q: Can Cabergolin-CT tablets be altered (crushed or split) if the tablet does not have a score line?

According to regulatory documents, the tablets are designed to be scored. The structural scoring is included to facilitate accurate division for use in low-dose starting regimens and precise dose titration.

Q: Why is the start of Cabergolin-CT treatment often described as involving a gradual dose adjustment?

Official documents detail a gradual regimen, noting that adverse reactions are often observed more frequently during dose escalation. This suggests that the slow titration schedule is utilized to manage the patient's tolerability of the medicine.

Q: Are there any documented effects of Cabergolin-CT on fertility?

Official sources indicate that for women with hyperprolactinemia, the drug is known to restore normal menstrual cycles and ovulation. This restoration addresses the underlying hormonal imbalance that can affect fertility.

Q: Is hair loss a reported side effect of Cabergolin-CT?

Regulatory labels list Alopecia (the medical term for hair loss) as an uncommonly reported adverse reaction associated with Cabergolin-CT use.

Q: What information is available regarding weight changes (gain or loss) while using Cabergolin-CT?

Regulatory labels list both Weight decreased and Weight increased as uncommonly reported adverse reactions. This indicates that changes in weight have been observed during treatment.

Q: How often are severe side effects associated with Cabergolin-CT reported in clinical data?

Official documents classify serious effects, such as fibrotic disorders and valvular heart disease. Their frequency is often listed under categories such as Rare or Very Rare in regulatory documents, rather than listing a precise numerical frequency for all serious events.

Q: What is the non-directive guidance for a patient who forgets to take a scheduled dose of Cabergolin-CT?

Official regulatory guidance addresses how a missed dose should be handled, advising against taking a double dose. Patients should refer to their provided patient information leaflet for specific instructions.

Q: Is a change in appetite a common and expected occurrence after beginning Cabergolin-CT?

Official product information indicates that Appetite decreased is listed as a common side effect associated with the use of Cabergolin-CT.

Q: Does Cabergolin-CT have any widely recognized alternative brand names?

The active ingredient in Cabergolin-CT, Cabergoline, is associated with various other brand names globally. The brand name Dostinex is widely recognized in regulatory and pharmaceutical literature.

How to Store and Dispose of Cabergolin-CT?

Cabergolin-CT tablets require storage at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and moisture and kept from freezing. Stability is maintained by storing the tablets in their original container, which must remain tightly closed with the supplied desiccant left inside.

Handling and Safety

All Cabergolin-CT must be stored out of the sight and reach of children and away from pets.

Disposal Instructions

Do not throw away unused or expired tablets in household waste or flush them down the toilet. Disposal must strictly adhere to local requirements for pharmaceutical waste; consult a pharmacist or healthcare provider for guidance on appropriate local take-back programs.